Categories: aggregated

The Corporatization of Psychedelics: FDA Fast-Tracking, Patents, and Pharma

President Trump signed Executive Order 14401, directing the FDA to fast-track review of psychedelic compounds and cutting the standard ten-to-twelve-month review down to as little as one to two months via “National Priority Vouchers.”

Jason

Share
Published by
Jason

Recent Posts

The Case That Just Blocked Trump’s Press Ban Started With High Times’ Founder and a Pie

In 1970, Tom Forçade put a pie in a federal commissioner’s face. When the government…

11 minutes ago

Thailand Advances Medical-Only Cannabis Bill as Adult-Use Era Fades

Thailand is moving closer to putting its medical-only cannabis model into national law, with a…

11 minutes ago

The Generational Flip: Are Teens Ditching Weed While Seniors Are Using More? What the Latest US Data Shows

Cannabis use among U.S. teens has declined substantially even as adult-use legalization has expanded, challenging…

1 day ago

This Company Wants to Sell the ‘World’s First’ CBD Pain Tablet. Its Own Trial Didn’t Beat a Placebo.

An Australian company says its THC-free tablet could become the world’s first registered prescription CBD…

1 day ago

21 Million Marijuana Arrests: Why Cannabis Prohibition Failed in America

That's how many marijuana arrests American police reported between 1990 and 2025, according to FBI-derived…

2 days ago

Cheaper Flower, More Choice, No Surge in Use: The Netherlands’ Cannabis Pilot Delivers Its First Results

For decades, the Netherlands has lived with a long-standing contradiction known as the “backdoor problem”:…

3 days ago